Call for Abstracts

Solid Tumors: Cellular & Molecular Medicine

• Molecular alterations and tropomyosin receptor kinase (TRK) pathway aberrations
• Methods to detect molecular alterations
• Implication of TRK pathway aberrations in the pathogenesis of cancer

Solid Tumors: Genetic Testing & Biomarkers

• Role of NTRK gene fusion and impact of NTRK gene fusion/TRK testing in treatment algorithms
• Understanding the importance and relevance of biomarkers and cytogenetic testing
• Diagnostic Techniques

Solid Tumors: Immuno-Oncology

• Cellular immunotherapy: Chimeric antigen receptor (CAR) T cell therapy, Dendritic cell therapy
• Antibody therapy
• Cytokine therapy: Interferon, Interleukin
• Combination immunotherapy
• Polysaccharide-K
• Adoptive T-cell therapy
• Anti-CD47 therapy
• Anti-GD2 antibodies
• Immune checkpoints
• Oncolytic virus
• Neoantigens
• Ongoing clinical trials

Colorectal Cancer (CRC)

• Management and treatment of metastatic CRC
• Role of Tyrosine Kinase Inhibitors (TKIs) in metastatic CRC treatment algorithms
• Identification of appropriate treatment for patients with mCRC based on MOA and biomarkers
• Role of NTRK gene fusion and impact of NTRK gene fusion/TRK testing in treatment algorithms for CRC
• Understanding of efficacy and safety profiles of approved NTRK inhibitors
• Treatment and management of TRK fusion cancer
• Clinical case reports
• Latest treatment guidelines & recommendations

Small & Non-Small Cell Lung Cancer

• EGFR Diagnostics & Plasma Testing
• EGFRm+ NSCLC
• HER2+ NSCLC
• Extensive-Stage SCLC
• Non-Metastatic NSCLC
• Non-Small Cell ALK Positive
• Non-Small Cell ROS1 Positive
• Clinical case reports
• Latest treatment guidelines & recommendations

• Treatment and management of pediatric cancers, including fibrosarcoma, glioma, nephroma
• Role of NTRK gene fusion and impact of NTRK gene fusion/TRK testing in treatment algorithms
• Treatment and management of TRK fusion cancers in children
• Understanding of efficacy and safety profiles of approved NTRK inhibitors
• Clinical case reports
• Latest treatment guidelines & recommendations

• BRCA
• Digital Pathology
• Non-BRCA
• DNA Damage Response
• PARP Inhibition
• HER2+
• Metastatic HR+
• Triple Negative
• Clinical case reports
• Latest treatment guidelines & recommendations

Lymphoma

• Diffuse Large B-Cell Lymphoma
• Follicular Lymphoma
• Treatment landscape in relapsed/refractory indolent NHL
• Role of PI3K inhibition in treatment algorithms in relapsed/refractory indolent NHL
• Unmet need in Follicular lymphoma and management of high-risk patients (i.e. POD24)
• Role of PI3K and synergistic pathways in NHL (i.e. follicular lymphoma, marginal zone lymphoma, diffuse large B-cell lymphoma, T-cell lymphomas)
• Approved PI3K inhibitors for relapsed/refractory NHL
• Adverse event management and safety considerations of PI3K inhibitors based on patient factors and comorbidities
• Clinical case reports
• Latest treatment guidelines & recommendations

Hepatocellular Carcinoma (HCC)

• Treatment and management of unresectable HCC and Cholangiocarcinoma (CCA)
• Role of systemic therapy in HCC and CCA multidisciplinary treatment algorithms
• Role of TRK-fusion and impact of TRK-fusion testing in CCA treatment algorithms
• Treatment and management of TRK fusion cancer
• Understanding of efficacy and safety profiles of approved NTRK inhibitors
• Sequential use of LRT and multiple systemic therapies in unresectable HCC
• Prevention and management of adverse events due to systemic therapies, such as TKIs, IOs and others
• Clinical case reports
• Latest treatment guidelines & recommendations

Central Nervous System (CNS) Cancers

• Role of TRK-fusion and impact of TRK-fusion testing in treatment algorithms for local, regional and/or CNS cancers
• Management and treatment of CNS cancers
• Understanding of efficacy and safety profiles of approved NTRK inhibitors in local, regional and/or CNS cancers
• Role of Tyrosine Kinase Inhibitors (TKIs) in metastatic CNS cancer treatment algorithms
• Prevention and management of adverse events due to TKIs
• Clinical case reports
• Latest treatment guidelines & recommendations

Skin Cancer

• Basal cell carcinoma (BCC)
• Squamous cell carcinoma (SCC)
• Melanoma

• The authors for accepted abstracts for oral talks will need to record online presentation with the help of congress management team (preferably via Zoom)
• The authors for accepted abstracts for poster presentations will need to submit their E-Posters (ppt/video)
• All abstracts will be peer reviewed on rolling basis and presenting author will be notified once the committee decision is made.
• Abstracts must be submitted via online submission system ONLY. Abstracts submitted via email, fax or by post will not be considered.
• Please specify preferred presentation format.
• Multiple abstracts can be submitted for consideration by one person. But, only one talk per person would be allowed at the congress. Additional accepted abstracts for poster presentation, can be presented by another registered co-authors or by presenting author after paying additional administrative fees.
• Please select congress track and theme that best describes your submission.
• Abstract text must not exceed 450 words using 12-Regular Times New Roman font. In addition, up-to 3 tables and/or images can be submitted.
• All presenters and co-authors must disclose any commercial interest/financial relationship.
• Please proofread your abstract carefully before submission. Congress team will not be responsible for any typographical errors or other mistakes in the abstract.
• By submitting an abstract, the presenting author confirms on behalf of all co-authors that all necessary ethical approvals and copyright permissions are obtained and confirms the originality of the work.
• No further changes in the abstract will be permitted upon acceptance.
• For technical help regarding abstract submission, please contact conference secretariat via email: [email protected]